Skip to main navigation
MIRUM

Header Menu

  • Who We Are
    • About Mirum
    • Leadership
    • Board of Directors
  • Programs
    • Pipeline
    • Maralixibat
    • Volixibat
    • Publications & Presentations
  • Patients & Families
    • Clinical Trials
    • Expanded Access
    • Progressive Familial Intrahepatic Cholestasis (PFIC)
    • Alagille Syndrome (ALGS)
    • Biliary Atresia (BA)
    • Intrahepatic Cholestasis of Pregnancy (ICP)
    • Primary Sclerosing Cholangitis (PSC)
  • Investors & Media
    • News Releases
    • Events and Presentations
    • Corporate Governance
      • Documents & Charters
      • Board of Directors
      • Management
      • Committee Composition
    • Financials & Filings
      • SEC Filing
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Investment Calculator
    • Shareholder Services
      • Investor FAQs
      • Email Alerts
      • Contact IR
  • Careers
  • Contact Us
  • Menu

Investor Relations

  • News Releases
  • Events and Presentations
  • Corporate Governance
    • Documents & Charters
    • Board of Directors
    • Management
    • Committee Composition
  • Financials & Filings
    • SEC Filings
    • Analyst Coverage
  • Stock Information
    • Stock Quote & Chart
    • Historic Price Lookup
    • Investment Calculator
  • Shareholder Services
    • Investor FAQs
    • Contact IR
    • Email Alerts

Investor Tools

  • Print

    Print

  • RSS Feeds

    RSS Feeds

  • Email Alerts

    Email Alerts

  • Search

    Search

  • Contact IR

    Contact IR

  • Email Page

    Email Page

SEC Filings

SEC Filings

Filing date Form Description Filing Group Issuer View
Jan 09, 2020 424B4

Form of prospectus disclosing information facts events covered in both forms 424B1 424B3

Registration Statements
Mirum Pharmaceuticals, Inc.
0001193125-20-004784.pdf
0001193125-20-004784.rtf
0001193125-20-004784.xls
View HTML
Jan 08, 2020 EFFECT

EFFECT

Other
Mirum Pharmaceuticals, Inc.
9999999995-20-000041.pdf
9999999995-20-000041.rtf
View HTML
Jan 06, 2020 S-1

Registration statement for face-amount certificate companies

Registration Statements
Mirum Pharmaceuticals, Inc.
0001193125-20-002291.pdf
0001193125-20-002291.rtf
0001193125-20-002291.xls
EX-101.INS - XBRL INSTANCE DOCUMENT View HTML
Jan 02, 2020 4

Statement of changes in beneficial ownership of securities

3,4,5
Mirum Pharmaceuticals, Inc.
0001209191-20-000307.pdf
0001209191-20-000307.rtf
View HTML
Dec 27, 2019 8-K

Report of unscheduled material events or corporate event

Current Reports
Mirum Pharmaceuticals, Inc.
0001193125-19-324949.pdf
0001193125-19-324949.rtf
0001193125-19-324949.xls
View HTML
Dec 27, 2019 DRS

Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy

Registration Statements
Mirum Pharmaceuticals, Inc.
0000950123-19-012069.pdf
0000950123-19-012069.rtf
0000950123-19-012069.xls
View HTML
Dec 16, 2019 SC 13G

A statement of beneficial ownership of common stock by certain persons

Other
Mirum Pharmaceuticals, Inc.
0001172661-19-002410.pdf
0001172661-19-002410.rtf
0001172661-19-002410.xls
View HTML
Nov 06, 2019 8-K

Report of unscheduled material events or corporate event

Current Reports
Mirum Pharmaceuticals, Inc.
0001564590-19-040998.pdf
0001564590-19-040998.rtf
0001564590-19-040998.xls
View HTML
Nov 06, 2019 10-Q

Quarterly report which provides a continuing view of a company's financial position

Quarterly Filings
Mirum Pharmaceuticals, Inc.
0001564590-19-041030.pdf
0001564590-19-041030.rtf
0001564590-19-041030.xls
EX-101.INS - XBRL INSTANCE DOCUMENT View HTML
Oct 28, 2019 3

Initial filing by director officer or owner of more than ten percent.

3,4,5
Mirum Pharmaceuticals, Inc.
0001209191-19-054233.pdf
0001209191-19-054233.rtf
View HTML

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Current page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • …
  • Next page Next ›
  • Last page Last »
Displaying 61 - 70 of 142 results

Data provided by Kaleidoscope.

Header Menu

  • Who We Are
  • About Mirum
  • Leadership
  • Board of Directors
  • Programs
  • Pipeline
  • Maralixibat
  • Volixibat
  • Publications & Presentations
  • Patients & Families
  • Clinical Trials
  • Expanded Access
  • Progressive Familial Intrahepatic Cholestasis (PFIC)
  • Alagille Syndrome (ALGS)
  • Biliary Atresia (BA)
  • Intrahepatic Cholestasis of Pregnancy (ICP)
  • Primary Sclerosing Cholangitis (PSC)
  • Investors & Media
  • News Releases
  • Events and Presentations
  • Corporate Governance
  • Financials & Filings
  • Stock Information
  • Shareholder Services
  • Careers
  • Contact Us
© 2021 – Mirum Pharmaceuticals, Inc.
Scroll to top
  • Facebook
  • Twitter
  • LinkedIn